Healthcare / Medical DevicesShenzhen
$61.01
-4.59 (-7.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-155.5M · quality 45.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
64/100
B
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.6B
P/E
57.0x
↑EV/EBITDA
32.0x
↑ROE
6.2%
↑Gross Margin
32.8%
↓Debt/Equity
0.47
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+24.4%
FCF CAGR
—
FCF margin
-6.8%
FCF / Net income
-1.32x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.29B · net income $117.8M · FCF $-155.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.29B | $2.29B | $1.71B | $1.60B | $1.19B |
| Net Income | $117.8M | $117.8M | $66.8M | $107.3M | $102.5M |
| EBITDA | $227.4M | $227.4M | $143.6M | $154.5M | $134.5M |
| EPS | 1.04 | 1.04 | 0.63 | 1.02 | 0.99 |
| Gross Margin | 32.8% | 32.8% | 34.9% | 37.5% | 38.3% |
| Operating Margin | 11.9% | 11.9% | 12.7% | 12.5% | 13.1% |
| Net Margin | 5.2% | 5.2% | 3.9% | 6.7% | 8.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.47 | 0.47 | 0.66 | 0.24 | 0.01 |
| Current Ratio | 2.23 | 2.23 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-155.5M | $-155.5M | $35.8M | $-734.8M | $-467.1M |
| Returns | |||||
| ROE | 6.2% | 6.2% | 3.7% | 6.1% | 6.2% |
| Valuation | |||||
| P/E | 57.02 | 57.02 | 29.05 | 24.70 | 38.05 |
| EV/EBITDA | 32.01 | 32.01 | 14.29 | 18.19 | 27.25 |
| P/B | 3.62 | 3.62 | 1.06 | 1.51 | 2.36 |
| Growth & Yield | |||||
| Revenue Growth | 33.9% | 33.9% | 6.6% | 34.7% | — |
| EPS Growth | 65.1% | 65.1% | -38.2% | 3.0% | — |
| Dividend Yield | 0.3% | 0.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
73.3%
EPS terminal req.
$5.41
Spread vs growth
-8.2%
5Y implied EPS CAGR
44.5%
EPS terminal req.
$6.55
Spread vs growth
20.6%
10Y implied EPS CAGR
26.1%
EPS terminal req.
$10.55
Spread vs growth
39.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+155.1%
Start / end P/E
38.0x → 58.7x
EPS bridge
0.63 → 1.04
Residual
+35.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.